AAV Reference Standard

About Agathos Biologics

Agathos Biologics is a private, pre-revenue biotech firm developing an ethical cell line platform for biomanufacturing, specifically targeting the recombinant adeno-associated virus (rAAV) production market for gene therapies. Its core technology, the AE1-BHK cell line, is offered as an alternative to controversial HEK293 cells, aiming to address scalability and ethical concerns in the industry. The company is led by a seasoned team with deep experience in gene therapy and biomanufacturing, and it is actively pursuing internal therapeutic programs and collaborations.

Therapeutic Areas